NEW YORK, March 28, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of PTC Therapeutics, Inc. (“PTC” or the “Company”) (Nasdaq:PTCT) between May 7, 2014 and February 29, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the District of New Jersey. If you purchased or otherwise acquired PTC securities between May 7, 2014 and February 29, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/ptc-therapeutics.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects.
On February 23, 2016, PTC announced that it received a Refuse to File letter from the United States Food and Drug Administration (“FDA”) regarding the New Drug Application for Translarna. The FDA stated in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review. Then on February 29, 2016, the Company’s CEO acknowledged that, according to the FDA, the Company did not provide substantial scientific evidence of effectiveness as it eliminated “data from a majority of enrolled patients.”
If you suffered a loss in PTC you have until May 2, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/ptc-therapeutics.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion
How Technology Is Reshaping Modern Business: From Operations to Customer Experience
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries”
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 



